Literature DB >> 2655084

High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans.

H Lee1, P Swanson, V S Shorty, J A Zack, J D Rosenblatt, I S Chen.   

Abstract

Confirmed infection with HTLV-II (human T cell leukemia virus type II) has been described only in rare cases. The major limitation to serological diagnosis of HTLV-II has been the difficulty of distinguishing HTLV-II from HTLV-I (human T cell leukemia virus type I) infection, because of substantial cross-reactivity between the viruses. A sensitive modification of the polymerase chain reaction method was used to provide unambiguous molecular evidence that a significant proportion of intravenous drug abusers are infected with HTLV, and the majority of these individuals are infected with HTLV-II rather than HTLV-I. Of 23 individuals confirmed by polymerase chain reaction analysis to be infected with HTLV, 21 were identified to be infected with HTLV-II, and 2 were infected with HTLV-I. Molecular identification of an HTLV-II--infected population provides an opportunity to investigate the pathogenicity of HTLV-II in humans.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2655084     DOI: 10.1126/science.2655084

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  89 in total

1.  Human T cell leukaemia/lymphoma virus infection in pregnant women in the United Kingdom: population study.

Authors:  A E Ades; S Parker; J Walker; M Edginton; G P Taylor; J N Weber
Journal:  BMJ       Date:  2000-06-03

2.  Significance of indeterminate reactivity to human T-cell lymphotropic virus in western blot analysis of individuals at risk.

Authors:  F J Medrano; V Soriano; E J Calderón; C Rey; M Gutiérrez; R Bravo; M Leal; J González-Lahoz; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

3.  Polymerase chain reaction (PCR) amplification demonstrates the absence of human T-cell lymphotrophic virus (HTLV)-I specific pol sequences in peripheral T-cell lymphomas.

Authors:  T Henni; M Divine; P Gaulard; C Haioun; M Duc Dodon; M F Gourdin; L Desforges; M Goossens; F Reyes; J P Farcet
Journal:  J Clin Immunol       Date:  1990-09       Impact factor: 8.317

4.  Low predictive value of polymerase chain reaction for diagnosis of cytomegalovirus disease in liver transplant recipients.

Authors:  R Delgado; C Lumbreras; C Alba; M A Pedraza; J R Otero; R Gómez; E Moreno; A R Noriega; C V Payá
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

5.  Primary isolation of human T-cell leukemia-lymphoma virus types I and II: use for confirming infection in seroindeterminate blood donors.

Authors:  B Hjelle; R Mills; C Goldsmith; S G Swenson; S Cyrus
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

Review 6.  Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2.

Authors:  Gerold Feuer; Patrick L Green
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

7.  Sensitive and specific polymerase chain reaction assays for diagnosis of human T-cell lymphotropic virus type I (HTLV-I) and HTLV-II infections in HTLV-I/II-seropositive individuals.

Authors:  W Heneine; R F Khabbaz; R B Lal; J E Kaplan
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

8.  Comparison of six commercial human T-cell lymphotropic virus type I (HTLV-I) enzyme immunoassay kits for detection of antibody to HTLV-I and -II.

Authors:  C Cossen; S Hagens; R Fukuchi; B Forghani; D Gallo; M Ascher
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

9.  Isolation of a C-type retrovirus from an HIV infected cell line.

Authors:  G Burtonboy; N Delferriere; B Mousset; M Heusterspreute
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

10.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.

Authors:  N R Landau; K A Page; D R Littman
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.